7Baggers

We provide you with 20 years of free, institutional-grade data for TARS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TARS. Explore the full financial landscape of TARS stock.

Reported DateCIKTickerType
2025-08-061819790TARS10-QUrl
2025-05-011819790TARS10-QUrl
2025-02-251819790TARS10-KUrl
2024-11-131819790TARS10-QUrl
2024-08-081819790TARS10-QUrl
2024-05-081819790TARS10-QUrl
2024-02-271819790TARS10-KUrl
2023-11-091819790TARS10-QUrl
2023-08-101819790TARS10-QUrl
2023-05-091819790TARS10-QUrl
2023-03-171819790TARS10-KUrl
2022-11-091819790TARS10-QUrl
2022-08-111819790TARS10-QUrl
2022-05-111819790TARS10-QUrl
2022-03-141819790TARS10-KUrl
2021-11-101819790TARS10-QUrl
2021-08-051819790TARS10-QUrl
2021-05-111819790TARS10-QUrl
2021-03-311819790TARS10-KUrl
2020-11-251819790TARS10-QUrl
2020-09-251819790TARSS-1Url

Tarsus Pharmaceuticals, Inc
(NASDAQ:TARS) 

TARS stock logo

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis cau...

Founded: 2016
Full Time Employees: 18
CEO / Co-Founder: Bobak Azamian 
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about TARS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.